142 related articles for article (PubMed ID: 23732306)
1. Conserved water mediated H-bonding dynamics of Ser117 and Thr119 residues in human transthyretin-thyroxin complexation: inhibitor modeling study through docking and molecular dynamics simulation.
Banerjee A; Bairagya HR; Mukhopadhyay BP; Nandi TK; Mishra DK
J Mol Graph Model; 2013 Jul; 44():70-80. PubMed ID: 23732306
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
3. Structural insight to mutated Y116S transthyretin by molecular dynamics simulation.
Banerjee A; Bairagya HR; Mukhopadhyay BP; Nandi TK; Bera AK
Indian J Biochem Biophys; 2010 Aug; 47(4):197-202. PubMed ID: 21174946
[TBL] [Abstract][Full Text] [Related]
4. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
[TBL] [Abstract][Full Text] [Related]
5. Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two thyroxine binding sites.
Tomar D; Khan T; Singh RR; Mishra S; Gupta S; Surolia A; Salunke DM
PLoS One; 2012; 7(9):e43522. PubMed ID: 22973437
[TBL] [Abstract][Full Text] [Related]
6. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
[TBL] [Abstract][Full Text] [Related]
7. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
8. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?
Palaninathan SK
Curr Med Chem; 2012; 19(15):2324-42. PubMed ID: 22471981
[TBL] [Abstract][Full Text] [Related]
9. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y
Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294
[TBL] [Abstract][Full Text] [Related]
10. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis.
Raghu P; Sivakumar B
Biochim Biophys Acta; 2004 Dec; 1703(1):1-9. PubMed ID: 15588697
[TBL] [Abstract][Full Text] [Related]
11. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution.
Sebastião MP; Lamzin V; Saraiva MJ; Damas AM
J Mol Biol; 2001 Mar; 306(4):733-44. PubMed ID: 11243784
[TBL] [Abstract][Full Text] [Related]
12. Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro.
Cascella R; Conti S; Mannini B; Li X; Buxbaum JN; Tiribilli B; Chiti F; Cecchi C
Biochim Biophys Acta; 2013 Dec; 1832(12):2302-14. PubMed ID: 24075940
[TBL] [Abstract][Full Text] [Related]
13. Ligand binding at the transthyretin dimer-dimer interface: structure of the transthyretin-T4Ac complex at 2.2 Angstrom resolution.
Neumann P; Cody V; Wojtczak A
Acta Crystallogr D Biol Crystallogr; 2005 Oct; 61(Pt 10):1313-9. PubMed ID: 16204882
[TBL] [Abstract][Full Text] [Related]
14. The binding of synthetic triiodo l-thyronine analogs to human transthyretin: molecular basis of cooperative and non-cooperative ligand recognition.
Trivella DB; Sairre MI; Foguel D; Lima LM; Polikarpov I
J Struct Biol; 2011 Feb; 173(2):323-32. PubMed ID: 20937391
[TBL] [Abstract][Full Text] [Related]
15. Crystal structures of human transthyretin complexed with glabridin.
Yokoyama T; Kosaka Y; Mizuguchi M
J Med Chem; 2014 Feb; 57(3):1090-6. PubMed ID: 24422526
[TBL] [Abstract][Full Text] [Related]
16. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.
Almeida MR; Macedo B; Cardoso I; Alves I; Valencia G; Arsequell G; Planas A; Saraiva MJ
Biochem J; 2004 Jul; 381(Pt 2):351-6. PubMed ID: 15080795
[TBL] [Abstract][Full Text] [Related]
17. Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition.
Julius RL; Hawthorne MF
Drug News Perspect; 2008 Jun; 21(5):258-66. PubMed ID: 18596990
[TBL] [Abstract][Full Text] [Related]
18. Thyroxine interactions with transthyretin: a comparison of 10 different naturally occurring human transthyretin variants.
Rosen HN; Moses AC; Murrell JR; Liepnieks JJ; Benson MD
J Clin Endocrinol Metab; 1993 Aug; 77(2):370-4. PubMed ID: 8345041
[TBL] [Abstract][Full Text] [Related]
19. Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy, Portuguese type.
Saraiva MJ; Costa PP; Goodman DS
J Lab Clin Med; 1983 Oct; 102(4):590-603. PubMed ID: 6311926
[TBL] [Abstract][Full Text] [Related]
20. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
Rodrigues JR; Simões CJ; Silva CG; Brito RM
Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
